Lexeo (LXEO) - Multiplikator Forward P/S
The forward price-to-sales ratio demonstrates the business resilience within an autonomous product cycle, where the metric is maintained at . Lexeo Therapeutics (LXEO) focuses on developing genetic drugs for the treatment of heart and brain pathologies by investing in R&D. The company's success depends on the safety of gene delivery and regulatory approval of new therapies for cardiovascular diseases.
Rincian metrik lan analitis perusahaan lexeotx.com (LXEO)
- rega pasar lan target rega analis:
- indikator kapitalisasi pasar:
- statistik nilai buku emiten:
- indikator beban kredit lan likuiditas emiten:
Rasio Total Utang marang Ekuitas Lexeo Therapeutics|LXEO - Utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Lexeo Therapeutics, Inc.|LXEO - Tanggungan utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Lexeo Therapeutics, Inc.|LXEO - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan Lexeo Therapeutics|Likuiditas cepet lexeotx.com
- data bathi bisnis lan rasio investasi:
LXEO - Asil keuangan resik|Bathi sing dikarepake Lexeo Therapeutics|LXEO - Rasio rega marang bathi|Prakiraan rega marang bathi Lexeo Therapeutics, Inc.|LXEO - Rasio P/E diaturake wutah|Pangali EV/EBITDA Lexeo Therapeutics, Inc.|LXEO - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Lexeo Therapeutics|LXEO - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi EPS kuartalan lexeotx.com|LXEO - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Lexeo Therapeutics
- informasi babagan volume dodolan lan pendapatan:
Analisis umum perusahaan:Lexeo LXEO
Capital is seeking to decouple resilient assets from speculative ones, utilizing the market capitalization-to-projected revenue ratio to determine fair business value. As Lexeo Therapeutics (LXEO) competes aggressively against biotech behemoths for a limited patient pool, the forward P/S multiple reflects market confidence in the therapy's commercial success, where any increase in the ratio elevates the risk of a sharp correction should certification be delayed.
Analisis perusahaan pesaing
Rasio rega marang prakiraan pendapatan Tempus AI, Inc. TEM|Rega forward marang dodolan QGEN|Ionis Pharma - Multiplikator Forward P/S|RGEN - Multiplikator Forward P/S|Avidity Biosciences (RNA) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan CRSP (crisprtx.com)|WGS (GeneDx) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Ultragenyx Pharmaceutical Inc. RARE|Multiplikator forward rega marang pendapatan BEAM (Beam Therapeutics Corp)|Multiplikator Forward P/S Sarepta Corp (SRPT)|Twist Bioscience - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake TXG (10xgenomics.com)|Intellia Therapeutics, Inc. - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Stoke Therapeutics Inc STOK|BLFS: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Wave Pharma|Rasio rega marang prakiraan pendapatan Maze Therapeutics Inc|sionnatx.com (SION) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Prime Medicine (PRME)|Rasio rega marang prakiraan pendapatan TSHA (Taysha Gene Therapies Inc)|uniQure Corp - Multiplikator forward rega marang pendapatan|MGTX: Kapitalisasi marang prakiraan pendapatan|REGENXBIO Inc. - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep solidbio.com|Ocugen (OCGN) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Pacific Biosciences of California, Inc. (PACB)|BNTC (Benitec) - Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan DSGN (Design Corp)|Rasio rega marang prakiraan pendapatan Rocket Pharmaceuticals (RCKT)|4dmoleculartherapeutics.com - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S KRRO (Korro Bio)|Multiplikator Forward P/S Editas Medicine Inc EDIT|SLN - Rasio rega marang prakiraan pendapatan|PRQR: Rasio rega marang prakiraan pendapatan|CDXS: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep sangamo.com (SGMO)|Multiplikator forward rega marang pendapatan NAUT|Kapitalisasi marang prakiraan pendapatan MGX (Metagenomi Inc.)|Multiplikator Forward P/S DTIL|GBIO - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan Boundless Bio, Inc. BOLD|Exicure Inc. (XCUR) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|IMNN: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan PHIO (Phio Pharmaceuticals)|MBIO (mustangbio.com) - Multiplikator forward rega marang pendapatan|RNAZ: Rasio rega marang pendapatan sing dikarepake|BNGO (Bionano Genomics Inc.) - Multiplikator Forward P/S|APDN: Rega forward marang dodolan|Multiplikator Forward P/S BLUE|IPA - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan Omega OMGA|Rega forward marang dodolan OMIC|Regulus Therapeutics - Multiplikator Forward P/S|SYRS - Multiplikator Forward P/S|Telesis Bio (TBIO) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan TCON (TRACON Pharmaceuticals Inc.)|UBX (Unity Bio) - Multiplikator Forward P/S
